Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 292, Issue 2, 2007, Pages

  Boerrigter, Guido ^a   Costello Boerrigter, Lisa C ^a   Harty, Gail J ^a   Lapp, Harald ^b   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

^b HELIOS KLINIKUM ERFURT   (Germany)

Author keywords

BNP 3 32; Cardiorenal regulation; Enzymatic degradation product; Hormone

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE[1-32]; BRAIN NATRIURETIC PEPTIDE[3-32]; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEGRADATION; DIURESIS; DIURETIC ACTIVITY; HEART OUTPUT; HEART RATE; HOMEOSTASIS; HORMONAL REGULATION; IMMUNOREACTIVITY; KIDNEY BLOOD FLOW; MALE; NONHUMAN; PRIORITY JOURNAL; SODIUM URINE LEVEL; VASODILATATION;

ANIMALS; ANTIGENS, CD26; BLOOD PRESSURE; CARDIAC OUTPUT; DIURESIS; DOGS; HEART; HEART RATE; HORMONES; KIDNEY; KIDNEY FUNCTION TESTS; MALE; NATRIURETIC PEPTIDE, BRAIN; NEUROTRANSMITTER AGENTS; RENAL CIRCULATION; URODYNAMICS; VASCULAR RESISTANCE; VASODILATION; WATER-ELECTROLYTE BALANCE;

EID: 33846794760     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00569.2006     Document Type: Article

References (24)

1. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27: 2874-2880, 2004.
2. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28: 55-72, 2006.
3. Boerrigter G, Burnett JC Jr. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs 13: 643-652, 2004.
4. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S, De Meester, I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 52: 82-87, 2006.
5. Florkowski CM, Richards AM, Espiner EA, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men. Am J Physiol Regul Integr Comp Physiol 266: R1244-R1250, 1994.
6. Fuhr JJ, Kaczmarczyk KJ, Kruttgen CD. Eine einfache colormetrische Methode zur Inulinbestimmung fuer Nieren-Clearance-Untersuchungen bei Stoffwechselgesunden und Diabetikern. Klin Wochenschr 33: 729-733, 1955.
7. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 108: 277-292, 2005.
8. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JCJ. Cyclic GMP activating actions and assay detection of altered forms of BNP in vitro (Abstract). Circulation 114, Supplement II, 720, 3385, 2006.
9. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 291: 83-88, 1993.
10. Lambeir AM, Durinx C, Scharpe S, De Meester, I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40: 209-294, 2003.
11. Lendeckel U, Arndt M, Wrenger S, Nepple K, Huth C, Ansorge S, Klein HU, Goette A. Expression and activity of ectopeptidases in fibrillating human atria. J Mol Cell Cardiol 33: 1273-1281, 2001.
12. Lisy O, Lainchbury JG, Leskinen H, Burnett JCJ. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension 37: 1089-1094, 2001.
13. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, Duc P, Westheim A, Omland T, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106: 416-422, 2002.
14. Ozaki J, Shimizu H, Hashimoto Y, Itoh H, Nakao K, Inui K. Enzymatic inactivation of major circulating forms of atrial and brain natriuretic peptides. Eur J Pharmacol 370: 307-312, 1999.
15. Papies B, Frille J, Gunther KH, Wagenknecht C. Isoenzyme (lactate dehydrogenase, aspartate aminotransferase) and dipeptidyl peptidase IV activity changes in blood plasma likely indicative of organ involvement due to arterial hypertension. Cor Vasa 33: 218-226, 1991.
16. Pidgeon GB, Richards AM, Nicholls MG, Espiner EA, Yandle TG, Frampton C. Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension. Hypertension 27: 906-913, 1996.
17. Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 123: 439-445, 2005.
18. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, Zwiener M, Baba HA, Yanagisawa M, Kuhn M. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 115: 1666-1674, 2005.
19. Scarborough RM, Schenk DB, McEnroe GA, Arfsten A, Kang LL, Schwartz K, Lewicki JA. Truncated atrial natriuretic peptide analogs. Comparison between receptor binding and stimulation of cyclic GMP accumulation in cultured vascular smooth muscle cells. J Biol Chem 261: 12960-12964, 1986.
20. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, Sugita K, Yamada K. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 316: 129-135, 2002.
21. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97: 4239-4244, 2000.
22. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC Jr. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91: 1127-1134, 2002.
23. Von Geldern TW, Rockway TW, Davidsen SK, Budzik GP, Bush EN, Chu-Moyer MY, Devine EM Jr, Holleman WH, Johnson MC, Lucas SD, Pollock DM, Smital JM, Thomas SM, Opgenorth TJ. Small atrial natriuretic peptide analogues: design, synthesis, and structural requirements for guanylate cyclase activation. J Med Chem 35: 808-816, 1992.
24. Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA 97: 8525-8529, 2000.